Arthritis Research & Therapy (Dec 2017)
Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study
- Isabel Ferreira,
- Sara Croca,
- Maria Gabriella Raimondo,
- Manjit Matharu,
- Sarah Miller,
- Ian Giles,
- David Isenberg,
- Yiannis Ioannou,
- John G. Hanly,
- Murray B. Urowitz,
- Nicole Anderson,
- Cynthia Aranow,
- Anca Askanase,
- Sang-Cheol Bae,
- Sasha Bernatsky,
- Ian N. Bruce,
- Jill Buyon,
- Ann E. Clarke,
- Mary Anne Dooley,
- Paul Fortin,
- Ellen Ginzler,
- Dafna Gladman,
- Caroline Gordon,
- Murat Inanc,
- Søren Jacobsen,
- Kenneth Kalunian,
- Diane Kamen,
- Munther Khamashta,
- Sam Lim,
- Susan Manzi,
- Joan Merrill,
- Ola Nived,
- Christine Peschken,
- Michelle Petri,
- Rosalind Ramsey-Goldman,
- Guillermo Ruiz-Irastorza,
- Jorge Sanchez-Guerrero,
- Kristjan Steinson,
- Gunnar K. Sturfelt,
- Ronald van Vollenhoven,
- Daniel J. Wallace,
- Asad Zoma,
- Anisur Rahman
Affiliations
- Isabel Ferreira
- Centre for Rheumatology Research, University College London, Fourth Floor Rayne Institute
- Sara Croca
- Centre for Rheumatology Research, University College London, Fourth Floor Rayne Institute
- Maria Gabriella Raimondo
- Centre for Rheumatology Research, University College London, Fourth Floor Rayne Institute
- Manjit Matharu
- Headache Group, Institute of Neurology and The National Hospital for Neurology and Neurosurgery
- Sarah Miller
- Headache Group, Institute of Neurology and The National Hospital for Neurology and Neurosurgery
- Ian Giles
- Centre for Rheumatology Research, University College London, Fourth Floor Rayne Institute
- David Isenberg
- Centre for Rheumatology Research, University College London, Fourth Floor Rayne Institute
- Yiannis Ioannou
- Centre for Rheumatology Research, University College London, Fourth Floor Rayne Institute
- John G. Hanly
- Division of Rheumatology, Dalhousie University and Queen Elizabeth II Health Sciences Center
- Murray B. Urowitz
- Lupus Program, Centre for Prognosis Studies in The Rheumatic Disease and Krembil Research Institute, Toronto Western Hospital, University of Toronto
- Nicole Anderson
- Lupus Program, Centre for Prognosis Studies in The Rheumatic Disease and Krembil Research Institute, Toronto Western Hospital, University of Toronto
- Cynthia Aranow
- Feinstein Institute for Medical Research
- Anca Askanase
- Rheumatology, Columbia University
- Sang-Cheol Bae
- Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases
- Sasha Bernatsky
- Divisions of Clinical Epidemiology and Rheumatology, McGill University Health Centre
- Ian N. Bruce
- Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, The University of Manchester, and NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre
- Jill Buyon
- New York School of Medicine
- Ann E. Clarke
- Division of Rheumatology, Cumming School of Medicine, University of Calgary
- Mary Anne Dooley
- Thurston Arthritis Research Center, University of North Carolina
- Paul Fortin
- Centre Hospitalier de l’Université Laval (CHUL)
- Ellen Ginzler
- Downstate Medical Center Rheumatology
- Dafna Gladman
- Lupus Program, Centre for Prognosis Studies in The Rheumatic Disease and Krembil Research Institute, Toronto Western Hospital, University of Toronto
- Caroline Gordon
- Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham
- Murat Inanc
- Department of Internal Medicine, Istanbul University
- Søren Jacobsen
- Copenhagen Lupus and Vasculitis Clinic, Centre For Rheumatology and Spine Diseases
- Kenneth Kalunian
- University of California
- Diane Kamen
- Division of Rheumatology and Immunology, Medical University of South Carolina
- Munther Khamashta
- FRCP Division of Women’s Health, King’s College
- Sam Lim
- Department of Medicine, Emory University
- Susan Manzi
- Allegheny Health Network
- Joan Merrill
- Clinical Pharmacology, Oklahoma Medical Research Foundation
- Ola Nived
- Department of Rheumatology, Lund University
- Christine Peschken
- Department of Medicine, Rady Faculty of Health Sciences, University of Manitoba
- Michelle Petri
- Johns Hopkins University School of Medicine
- Rosalind Ramsey-Goldman
- Northwestern University, Feinberg School of Medicine
- Guillermo Ruiz-Irastorza
- Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute. Hospital Universitario Cruces, University of the Basque Country
- Jorge Sanchez-Guerrero
- Mount Sinai Hospital and University Health Network, University of Toronto
- Kristjan Steinson
- Department of Rheumatology, Landspitali University Hospital
- Gunnar K. Sturfelt
- Department of Rheumatology, Lund University
- Ronald van Vollenhoven
- Rheumatology Unit, Department of Medicine, Karolinska University Hospital
- Daniel J. Wallace
- Cedars-Sinai Medical Center/David Geffen School of Medicine at UCLA
- Asad Zoma
- Department of Rheumatology Hairmyres Hospital
- Anisur Rahman
- Centre for Rheumatology Research, University College London, Fourth Floor Rayne Institute
- DOI
- https://doi.org/10.1186/s13075-017-1495-6
- Journal volume & issue
-
Vol. 19,
no. 1
pp. 1 – 9
Abstract
Abstract Background In patients with systemic lupus erythematosus (SLE) there is no serological test that will reliably distinguish neuropsychiatric (NP) events due to active SLE from those due to other causes. Previously we showed that serum levels of nitrated nucleosomes (NN) were elevated in a small number of patients with NPSLE. Here we measured serum NN in samples from a larger population of patients with SLE and NP events to see whether elevated serum NN could be a marker for NPSLE. Methods We obtained serum samples from patients in the Systemic Lupus International Collaborative Clinics (SLICC) inception cohort. This included 216 patients with NP events and two matched controls with SLE but no NP events for each of these patients. For the NP patients we tested samples taken before, during and after the NP event. Results Twenty-six patients had events attributed to SLE according to the most stringent SLICC attribution rule. In these patients there was no association between onset of event and elevated serum NN. In 190 patients in whom events were not attributed to SLE by the SLICC rules, median serum NN was elevated at the onset of event (P = 0.006). The predominant clinical features in this group of 190 patients were headache, mood disorders and anxiety. Conclusions Serum NN levels rise at the time of an NP event in a proportion of patients with SLE. Further studies are needed to determine the value of serum NN as a biomarker for NPSLE.
Keywords
